Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL11790867 | 0.98 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| Hydrochloric Acid SCHEMBL11158946 | 0.98 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL30577265 | 0.88 | SMN1; SMN2 (0.81) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL31349930 | 0.86 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL11158941 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL864429 | 0.86 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL11790860 | 0.85 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL3183964 | 0.85 | ALDH1A1 (0.63) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL2093174 | 0.84 | NPC1 (0.59) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL10039554 | 0.84 | HPGD (0.68) | SMN1; SMN2NPC1RAB9AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110743517-A | Preparation process of polysaccharide derivative coating type chiral stationary phase | 浙江华谱新创科技有限公司 | 2020-02-04 | — | — | CN | claimed |
| US-9353096-B2 | Substituted phenylcarbamate compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-31 | — | — | US | claimed |
| EP-2906544-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | claimed |
| US-20150218144-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | claimed |
| WO-2014056958-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | claimed |
| US-12403447-B2 | Separating agent for optical isomers | DAICEL CORPORATION (JP) | 2025-09-02 | — | — | US | disclosed |
| US-20250128237-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR METALS, CHIRAL MOLECULES, OR BOTH | DONALDSON COMPANY, INC. | 2025-04-24 | — | — | US | disclosed |
| CN-119186531-A | Chiral stationary phase derivatized by multi-functional hydroxypropyl-beta-cyclodextrin, preparation method and application thereof | 浙江工业大学 | 2024-12-27 | — | — | CN | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| JP-2024060213-A | Method for improving separation performance of stationary phase for column chromatography | 株式会社ダイセル | 2024-05-02 | — | — | JP | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-1773802-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006011047-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060020022-A1 | Enantioselective separation method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| EP-1073618-B1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY PURE OR OPTICALLY ENRICHED SERTRALINE-TETRALONE USING CONTINUOUS CHROMATOGRAPHY | PFIZER PROD INC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1073618-A1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY PURE OR OPTICALLY ENRICHED SERTRALINE-TETRALONE USING CONTINUOUS CHROMATOGRAPHY | Pfizer Products Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057089-A1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY PURE OR OPTICALLY ENRICHED SERTRALINE-TETRALONE USING CONTINUOUS CHROMATOGRAPHY | PFIZER PRODUCTS INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| US-4826527-A | Aminophenylmethyl isoxazolidinones as plant regulators | FMC CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| US-4552585-A | Herbicidal 2-(aminophenyl)methyl derivatives of 3-isoxazolidinones or 3-oxazinones | FMC CORPORATION (US) | 1985-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | SMN1; SMN2 3197/4885NPC1 285/4885RAB9A 3175/4885 |
| US-20150218144-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | SMN1; SMN2 2337/4885NPC1 677/4885RAB9A 3982/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | SMN1; SMN2 187/4885NPC1 330/4885RAB9A 3771/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | SMN1; SMN2 3197/4885NPC1 285/4885RAB9A 3175/4885 |
| US-20060020022-A1 | Enantioselective separation method | SLC7A1, SLC10A1, DHCR7 | SMN1; SMN2 3170/4885NPC1 307/4885RAB9A 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.